Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine effect on Methadone PK
NCT02715700Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of doravirine in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve From Zero to 24 Hours After Dosing of R-Methadone, Plasma Concentration at 24 Hours After Dosing of R-Methadone and 10 more. Started Sep 2015; status: completed.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02715700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02715700.